Lexeo Therapeutics Reports First Quarter 2026 Financial Results and Operational Highlights
Lexeo Therapeutics reported Q1 2026 financial results and operational highlights, including FDA submission of SUNRISE-FA 2 pivotal trial protocol for LX2006, presentation of new data at ASGCT 2026, and a strong cash position of $227.6 million to fund operations into 2028. The company made progress in clinical trials for genetic cardiovascular disea…